caa a22 4500 477072062 CHVBK 20180405111429.0 cr unu---uuuuu 170330e19960701xx s 000 0 eng 10.1007/BF02627962 doi (NATIONALLICENCE)springer-10.1007/BF02627962 Effects of hypothyroidism on the Vulnerability to ventricular fibrillation in dogs: A comparative study with amiodarone [Elektronische Daten] [Pingming Liu, Lü Fei, Wei Wu, Jianming Li, Jingfeng Wang, Xuming Zhang] Summary: It has been shown that thyroid hormone has a significant effect on the heart and that suppression of thyroid function may contribute to the antiarrhythmic effect of amiodarone. The study was aimed at investigating the effects of hypothyroidism, compared with those of amiodarone, on vulnerability to ventricular fibrillation in dogs. In this study, 25 adult dogs were randomly divided into three groups: a hypothyroid group following total thyroidectomy (n=9), an amiodarone group (n=8, 400 mg per day, 4 weeks), and a control group (n=8). Both amiodarone and control groups were subjected to sham surgery. Five to 8 weeks after surgery, ventricular fibrillation threshold and other electrophys-iological parameters were determined. Right ventricular effective refractory period, monophasic action potential duration, and ventricular fibrillation threshold were significantly increased in both the thyroidectomized and amiodarone-treated animals. There was no significant change in monophasic action potential duration dispersion. The incidence of ventricular fibrillation during ischemia and reperfusion was significantly reduced in both treated groups compared with the sham-operated euthyroid controls. These observations suggest that hypothyroidism has a significant antifibrillatory effect in dogs. Homogeneous prolongation of repolarization and refractoriness may contribute to the antifibrillatory action of hypothyroidism. Kluwer Academic Publishers, 1996 hypothyroidism nationallicence amiodarone nationallicence ventricular repolarization nationallicence monophasic action potential nationallicence ventricular fibrillation threshold nationallicence Liu Pingming Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou, China aut Fei Lü Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou, China aut Wu Wei Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou, China aut Li Jianming Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou, China aut Wang Jingfeng Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou, China aut Zhang Xuming Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou, China aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/3(1996-07-01), 369-378 0920-3206 10:3<369 1996 10 10557 https://doi.org/10.1007/BF02627962 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02627962 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Liu Pingming Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou, China aut NATIONALLICENCE 700 1- Fei Lü Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou, China aut NATIONALLICENCE 700 1- Wu Wei Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou, China aut NATIONALLICENCE 700 1- Li Jianming Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou, China aut NATIONALLICENCE 700 1- Wang Jingfeng Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou, China aut NATIONALLICENCE 700 1- Zhang Xuming Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou, China aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/3(1996-07-01), 369-378 0920-3206 10:3<369 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer